Login to Your Account

AIDAC supports two new infectious disease weapons

By Mari Serebrov
Washington Editor

Tuesday, April 1, 2014
Citing the need for a bigger arsenal in the war against infectious diseases, the FDA’s Anti-infective Drugs Advisory Committee (AIDAC) unanimously supported approval Monday of two new weapons to treat acute bacterial skin and skin structure infections caused by certain gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription